Results from a Phase II clinical trial of Baxter International Incorporated's Gammagard have shown that it improved function and reduced cognition decline in patients with mild-to-moderate Alzheimer's disease. Baxter International conducted the clinical trial with New York Presbyterian Hospital/Weill Cornell Medical Center. Gammagard (immune globulin intravenous) is marketed as Kiovig outside of the US. The trial served to measure function and cognition in Alzheimer's patients who received uninterrupted Gammagard for 18 months. After this period, patients who received the treatment continuously averaged approximately 1.36 points higher in tests for function than patients who received a placebo. Patients who received Gammagard declined by around 9.15 fewer points in a test for cognition than those who were given placebo. According to the Alzheimer's Society, the disease is one of the most common forms of dementia. Symptoms include memory loss, confusion and difficulty with speech and understanding.feeds.directnews.co.uk /> ' class='boldLink'>feeds.directnews.co.uk Bookmark Using: feeds.directnews.co.uk alt="" /> del.icio.us target="_blank">Delicious feeds.directnews.co.uk alt="" /> digg.com target="_blank">Digg feeds.directnews.co.uk alt="" /> reddit.com target="_blank">reddit feeds.directnews.co.uk alt="" /> www.facebook.com target="_blank">Facebook feeds.directnews.co.uk alt="" /> www.stumbleupon.com target="_blank">StumbleUpon		UPCOMING CONFERENCES CRO & CMO Partnerships 2010 Berlin, Germany 26 - 27 May 2010 NextGen 2010 www.nextgen-2010.com ">NextGen 2010 < /> Mumbai, India 24 - 25 June 2010     ' class='boldLink'>ad.uk.doubleclick.net ad.doubleclick.net target="_blank">s0.2mdn.net />     Survey - X www.surveymonkey.com color="#ffffff" size="3" face="Verdana">HELP US IMPROVE Please fill out our survey and let us know how we could tailor WherePharmaMeets.com to serve the pharma community better. It's short.

Results from a Phase II clinical trial of Baxter International Incorporated's Gammagard have shown that it improved function and reduced cognition decline in patients with mild-to-moderate Alzheimer's disease.



Baxter International conducted the clinical trial with New York Presbyterian Hospital/Weill Cornell Medical Center.



Gammagard (immune globulin intravenous) is marketed as Kiovig outside of the US.



The trial served to measure function and cognition in Alzheimer's patients who received uninterrupted Gammagard for 18 months.



After this period, patients who received the treatment continuously averaged approximately 1.36 points higher in tests for function than patients who received a placebo.



Patients who received Gammagard declined by around 9.15 fewer points in a test for cognition than those who were given placebo.



According to the Alzheimer's Society, the disease is one of the most common forms of dementia. Symptoms include memory loss, confusion and difficulty with speech and understanding.feeds.directnews.co.uk />